ERBB2 and breast cancer: Our results support their conclusions that there was no difference in tolerance of palbociclib + endocrine therapy between patients aged ≥ 65 and other patients with HR-positive, HER2-negative advanced breast cancer; and a dose adjustment based on age is not required.